MHRA approves Vyjuvek for DEB wound treatment

On 15 May 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, approved beremagene geperpavec, sold as Vyjuvek, for the treatment of wounds in people with dystrophic epidermolysis bullosa, usually shortened to DEB. The approval covers use from birth onwards, making this an important development for families living with a condition that can make even gentle friction painful. (gov.uk)

If DEB is new to you, start with the basics. It is a rare genetic condition linked to a fault in a gene that helps hold layers of skin together. When that link is not working properly, skin can become extremely fragile, with blistering and wounds that return again and again. That is the first big point in this story. Vyjuvek is not about cosmetic healing or a minor skin complaint; it is aimed at wounds caused by a serious inherited condition. (gov.uk)

The treatment itself is unusually direct. Vyjuvek is a gel that is placed straight onto wounds. The MHRA says it uses a modified virus to deliver copies of the faulty gene into cells in the wound so the skin can heal more effectively, and it also stresses that the virus and genetic material in the medicine do not alter the patient's DNA. If you have heard the phrase gene therapy and felt unsure, that reaction is understandable. In this case, the medicine is designed to help at the wound site; it is not described by the regulator as changing the person's underlying DNA. (gov.uk)

The clinical evidence in the MHRA announcement comes from a study of 31 patients aged 1 to 44 with DEB. After 6 months, 67% of wounds treated with Vyjuvek were completely healed, compared with 22% of wounds given placebo, the comparison treatment used in the trial. Those numbers matter because they show a clear gap between the treated wounds and the untreated comparison. They also remind us to read medical evidence carefully: the trial was small, and the press release notes an approval from birth onwards even though the age range described in the study began at 1 year. (gov.uk)

There is also a useful lesson here about how medicine approval works in the UK. The licence was granted on 15 May 2026 to Krystal Biotech Netherlands, B.V., and the medicine was reviewed through the International Recognition Procedure, or IRP. According to MHRA guidance, that route lets the regulator take account of decisions already made by certain trusted regulators while still carrying out a targeted UK assessment and keeping the right to reject an application if the evidence is not strong enough. So this was not a case of the UK simply copying somebody else's decision. It was a UK approval reached through a route designed to move more quickly when a medicine has already been assessed elsewhere. (gov.uk)

For patients and families, what this means is practical rather than abstract. The UK now has an approved option specifically for DEB wounds. That does not read as a cure for every part of DEB; it reads as a new treatment aimed at helping wounds heal, which is exactly the licensed use described by the MHRA. The regulator has also said it will continue to monitor the medicine's safety and effectiveness as use becomes wider. That is standard and important, especially with a treatment for a rare condition that will now be used beyond a trial setting. (gov.uk)

One final piece of media literacy is worth keeping with you. A medicine approval is not just a scientific milestone; it is also a signal that the regulator believes the likely benefits outweigh the risks for a specific use. In this case, the next documents to watch are the Summary of Product Characteristics, which sets out how clinicians should use the medicine, and the Patient Information Leaflet, which explains safe use for patients. The MHRA said both would be published on its products website within 7 days of the approval. (gov.uk)